KIORA PHARMACEUTICALS INC

Kiora Pharmaceuticals, Inc. held its 2026 annual meeting of stockholders, where several key proposals were approved. Stockholders voted to amend the 2024 Equity Incentive Plan, increasing the number of shares available for issuance by 1,500,000. Additionally, three Class II Directors were elected, the compensation of named executive officers was approved on a non-binding advisory basis, and Haskell & White LLP was ratified as the independent registered public accounting firm for 2026.

Kiora Pharmaceuticals reported a Q1 2026 net loss of $(2.4) million, or $(0.58) per share, and ended the quarter with $13.9 million in cash and short-term investments. Subsequent to the quarter, the company secured a $5.0 million strategic equity financing, extending its operational runway into late 2028. The company also provided updates on its clinical programs, noting active enrollment in the Phase 2 ABACUS-2 study for KIO-301 with trial site expansion, and continued progress in the Phase 2 KLARITY study for KIO-104.

Kiora Pharmaceuticals reported a net loss of $(2.42) million for the first quarter of 2026, an increase from $(2.19) million in the prior year, with basic net loss per common share at $(0.58). Despite increased operating expenses and cash used in operations, the company's cash and cash equivalents rose to $10.96 million. Following a $5 million financing transaction in April 2026, Kiora Pharmaceuticals anticipates having sufficient cash to fund its planned operations into late 2028.

Kiora Pharmaceuticals, Inc. filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 10, 2026. Stockholders will vote on the election of three Class II directors, an advisory resolution on executive compensation, the ratification of Haskell & White LLP as auditors, and an amendment to increase shares authorized under the 2024 Equity Incentive Plan by 1,500,000 shares. The board recommends voting "FOR" all proposals.

Kiora Pharmaceuticals entered into a Securities Purchase Agreement to sell shares of common stock, pre-funded warrants, and common warrants in a private placement. The offering relies on exemptions from securities registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, indicating a transaction with accredited investors.

Kiora Pharmaceuticals has entered into a Securities Purchase Agreement with investors to sell shares of common stock, pre-funded warrants, and Tranche A-1 and A-2 common warrants. The agreement also includes a Registration Rights Agreement, granting investors certain registration rights for the shares and warrant shares.